PPARγ Inverse Agonist FX-909 Demonstrates Preliminary Efficacy in Advanced Urothelial Carcinoma: Phase 1 Trial Results

A first-in-class small-molecule inverse agonist of peroxisome proliferator-activated receptor gamma achieved objective responses in 17.5% of patients with urothelial carcinoma in a phase 1 dose-escalation study. The agent exhibited acceptable tolerability with grade 3 or higher adverse events primarily consisting of hematologic toxicities.